Skip to main content

Table 1 Demographic comparison between training and validation cohorts

From: A clinical-radiomics nomogram for the preoperative prediction of lymph node metastasis in colorectal cancer

Characteristic

Training cohort

Validation cohort

P

Age, mean SD

58.86 ± 12.38

59.12 ± 11.53

0.48

Tumor size, mean SD

4.48 ± 1.91

4.53 ± 1.82

0.25

Sex (%)

0.62

 Male

258.0 (60.71%)

167.0 (39.29%)

 

 Female

200.0 (58.65%)

141.0 (41.35%)

 

M stage (%)

0.56

 M0

399.0 (60.27%)

263.0 (39.73%)

 

 M1

59.0 (56.73%)

45.0 (43.27%)

 

CA19-9 (%)

0.94

 0–27 U/mL

362.0 (59.64%)

245.0 (40.36%)

 

 ≥27 U/mL

96.0 (60.38%)

63.0 (39.62%)

 

CEA (%)

0.08

 0–5 ng/mL

298.0 (62.34%)

180.0 (37.66%)

 

 ≥ 5 ng/mL

160.0 (55.56%)

128.0 (44.44%)

 

Location (%)

0.42

 Right

208.0 (61.54%)

130.0 (38.46%)

 

 Left

250.0 (58.41%)

178.0 (41.59%)

 

Grade (%)

0.63

 High

26.0 (5.68%)

21.0 (6.82%)

 

 Middle

301.0 (65.72%)

207.0 (67.21%)

 

 Low

131.0 (28.60%)

80.0 (25.97%)

 

Histotype (%)

0.93

 Adenocarcinoma

379.0 (82.75%)

258.0 (83.77%)

 

 Mucinous histology

74.0 (16.16%)

47.0 (15.26%)

 

 Signet ring cell differentiation

5.0 (1.09%)

3.0 (0.97%)

 
  1. Chi-Square or Fisher Exact tests, as appropriate, were used to compare the differences in categorical variables (gender, M stage, CA19-9 level, CEA level, location, grade, histotype), while a two-sample t-test was used to compare the differences in age and tumor size. Laboratory analysis of CEA and CA 19-9 were done via routine blood tests within 1 week before surgery. The threshold value for CEA level was ≤ 5 ng/mL and > 5 ng/mL and the threshold value for CA 19-9 level was ≤ 27 U/mL and > 27 U/mL, according to the normal range used in clinics
  2. CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9